麻豆传媒

News — BARCELONA – Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. The studies will be presented both in-person and online on September 13-17, 2024. A full list of Dana-Farber oral abstracts is available:

The conference, attended by more than 35,000 global oncology professionals, kicks off with a presentation by , founder and director of the Program for Young Adults with Breast Cancer at Dana-Farber, on addressing the unintended consequences of cancer care. Partridge will receive The ESMO Award during the opening session on September 13, 2024. 

Primary results of a pivotal breast cancer study (LBA18), DESTINYBreast-12, will be presented by associate chief of breast oncology at Dana-Farber. The research looks at trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastasis. Lin presents the findings as a late-breaking abstract in the Proffered Paper Session: Breast Cancer, metastatic, on Friday, September 13, 2024, 10:00am ET (16:00 CEST).

, director of the , led a phase 3 study (LBA73) looking at tivozanib-nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma following prior therapies including an immune checkpoint inhibitor. Choueiri is presenting data for the first time from the TiNivo-2 Study in the Proffered Paper Session 1: GU tumors, non-prostate, on Friday, September 13, 2024, 8:00am ET (14:00 CEST).

Data from the SOLARIS (Alliance A021703) study (LBA26) looking at vitamin D supplementation in patients with metastatic colorectal cancer will be presented by associate chief of gastrointestinal oncology at Dana-Farber. The study is a multicenter double-blind phase III randomized clinical trial looking at high-dose vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer. co-director of the colon and rectal cancer center at Dana-Farber, is the senior author. Ng presents findings during the Proffered Paper Session 2: GI tumors, lower, on Saturday, September 14, 2024, 9:35am ET (15:35 CEST).

Other key research from Dana-Farber includes:

Proffered paper session 1: GU tumors, non-prostate

• NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study (1690O)
• Toni Choueiri, MD, Dana-Farber, senior author
• Friday, September 13, 2024, 9:00am ET (15:00 CEST)

Proffered paper session 1: Developmental therapeutics

• Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors (612O)
• Elizabeth Buchbinder, MD, Dana-Farber, senior author
• Friday, September 13, 2024, 10:10am ET (16:10 CEST)

Mini oral session: NSCLC metastatic

• Updated Efficacy and Safety from the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC) (LBA56)
• Bruce Johnson, MD, Dana-Farber, senior author
• Saturday, September 14, 2024, 5:15am ET (11:15 CEST)

Proffered paper session: Supportive and palliative care

• Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial (1814O)
• Ann Partridge, MD, MPH, Dana-Farber, co-senior investigator
• Saturday, September 14, 2024, 8:45am ET (14:45 CEST)

Proffered paper session: Supportive and palliative care

• Breastfeeding after breast cancer in young BRCA carriers: results from an international cohort study (1815O)
• Ann Partridge, MD, MPH, Dana-Farber, co-senior investigator
• Saturday, September 14, 2024, 8:55am ET (14:55 CEST)

Mini oral session: Supportive and palliative care

• Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (1817 MO)
• Jennifer Ligibel, MD, Dana-Farber, presenting author
• Sunday, September 15, 2024, 4:15am ET (10:15 CEST) 

Mini oral session 2: Gynecological cancers

• A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer (719MO)
• Elizabeth Lee, MD, Dana-Farber, presenting author
• Sunday, September 15, 2024, 9:25am ET (15:25 CEST)

Proffered paper session: NETs and endocrine tumors

• Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses (1141O)
• Jennifer Chan, MD, MPH (Presenting Author); Jeffrey Meyerhardt, MD, MPH (Senior Author)
• Monday, September 16, 2024, 8:45am ET (14:45 CEST)
• Read more about the

A full list of Dana-Farber Presentations at the 2024 ESMO Congress is available here: .

For all ESMO-related media inquiries, contact Victoria Warren (617-939-5531, [email protected]). Follow the meeting live on X using the hashtag #ESMO24 and follow Dana-Farber 麻豆传媒 on X at .

About Dana-Farber Cancer Institute 

is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through and for children through . Dana-Farber is the only hospital nationwide with a top 5 U.S. 麻豆传媒 & World Report Best Cancer Hospital ranking in both adult and pediatric care.

###